title: Ten-year experience with living related donated splenic transplantation for the treatment of hemophilia A.
abstract: OBJECTIVE
  Six cases of hemophilia A treated with living related donated splenic transplantation (LRDST) were performed over 10 years.
  
  
  METHODS
  We reviewed the six consecutive cases of LRDST from 1992 to 2002. Three patients received whole spleen allografts and the other three, partial spleen allografts. All allografts were transplanted to the extraperitoneal space in the right iliac fossa by an end-to-end anastomosis between the splenic artery and the internal iliac artery and an end-to-side anastomosis between the splenic vein and the external (or common) iliac vein. After the operation, a combined regimen with cyclosporine, azathioprine, anti-lymphocyte globulin, OKT3, was administered to suppress the immune reaction.
  
  
  RESULTS
  The functional period of the allografts varied between 30 days to 4 years. Patient factor-VIII (F-VIII) levels rose from less than 5% before operation to 15% to 56% postoperatively. One patient died from central nervous system complications. Another lost his graft because exogenous F-VIII was not supplemented in timely fashion at the onset of rejection. And the third could no longer afford the expensive immunosuppressive drugs at 2 years after the operation and eventually lost the spleen. The remaining three patients presently have regained self-support, among whom one has survived for 4 years.
  
  
  CONCLUSIONS
  Though the sample pool is relatively small, our clinical observations tend to confirm LRDST as a feasible, effective treatment for hemophilia A.
authors.affiliation: Department of General Surgery, First Clinical Hospital of Harbin Medical University, Harbin, People' Republic of China.
authors.forename: H C
authors.initials: HC
authors.lastname: Jiang
authors.forename: Y
authors.initials: Y
authors.lastname: Gao
authors.forename: W J
authors.initials: WJ
authors.lastname: Dai
authors.forename: B
authors.initials: B
authors.lastname: Sun
authors.forename: J
authors.initials: J
authors.lastname: Xu
authors.forename: H Q
authors.initials: HQ
authors.lastname: Qiao
authors.forename: Q H
authors.initials: QH
authors.lastname: Meng
authors.forename: C J
authors.initials: CJ
authors.lastname: Wu
mesh_terms: D004359:Drug Therapy, Combination; D005190:Family; D005220:Fathers; D005260:Female; D006467:Hemophilia A / Q000601:surgery*; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D019520:Living Donors; D008297:Male; D009035:Mothers; D012189:Retrospective Studies; D013154:Spleen / Q000637:transplantation*; D013156:Splenectomy / Q000379:methods; D020858:Tissue and Organ Harvesting / Q000379:methods; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents